Narrative review / 2013
Early human trials suggest curcumin extract may offer benefits in several inflammatory conditions and pancreatic cancer, though late-phase trials are needed.
This review examines the pharmacology, efficacy, adverse effects, and dosage of curcuminoids and standardized curcumin extracts. Early human clinical trials suggest potential beneficial effects for conditions such as dyspepsia, peptic ulcer, inflammatory bowel disease, rheumatoid arthritis, osteoarthritis, uveitis, orbital pseudotumor, and pancreatic cancer. Curcumin is generally well-tolerated, with nausea and diarrhea being the most common side effects. The authors note that late-phase clinical trials are still required to confirm most beneficial effects.
- Study type
- Narrative review
- Who was studied
- Patients across early human clinical trials
- What was measured
- Efficacy, adverse effects, pharmacology, dosage, and standardization of curcumin
THE PAPER
Clinical utility of curcumin extract.
Asher GN, Spelman K. Altern Ther Health Med, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.